The Role of CD44 Isoforms in Endometrial Cancer
Author Information
Author(s): C Tempferl, G Haeusler, A Kaider, L Hefler, E Hanzal, A Reinthaller, G Breitenecker, Ch Kainz
Primary Institution: University of Vienna Medical School
Hypothesis
Is CD44 isoform expression a prognostic factor in endometrial cancer?
Conclusion
The expression of CD44 isoforms is not an adverse predictive factor in endometrial cancer.
Supporting Evidence
- CD44 isoforms were detected in 26% to 31% of tumor samples.
- CD44v6 expression showed an association with shortened overall survival.
- Multivariate analysis revealed CD44v6 not to be an independent prognostic factor.
Takeaway
This study looked at a protein called CD44 in cancer samples to see if it could help predict how patients would do. They found it doesn't really help with that.
Methodology
Immunohistochemistry was used to analyze CD44 isoform expression in 156 endometrial cancer specimens.
Limitations
The study did not include lymph node status in the analysis due to the study period.
Participant Demographics
Median age of patients was 59 years, with a range of 48-71 years.
Statistical Information
P-Value
0.06
Confidence Interval
0.97-8.1
Statistical Significance
p=0.06
Want to read the original?
Access the complete publication on the publisher's website